Compare RANI & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | SEER |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 108.0M |
| IPO Year | 2021 | 2020 |
| Metric | RANI | SEER |
|---|---|---|
| Price | $0.84 | $1.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 658.7K | 188.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.14 | 9.40 |
| EPS | ★ N/A | N/A |
| Revenue | $1,633,000.00 | ★ $16,578,000.00 |
| Revenue This Year | $274.77 | $2.14 |
| Revenue Next Year | $79.44 | $25.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 58.85 | 16.99 |
| 52 Week Low | $0.45 | $1.55 |
| 52 Week High | $3.87 | $2.41 |
| Indicator | RANI | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 39.86 |
| Support Level | $0.83 | $1.83 |
| Resistance Level | $0.92 | $1.99 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 11.23 | 16.55 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.